tradingkey.logo
tradingkey.logo
Search

Bausch + Lomb Corp

BLCO
Add to Watchlist
16.540USD
-0.090-0.54%
Close 06/30, 16:00ETQuotes delayed by 15 min
5.86BMarket Cap
LossP/E TTM

TradingKey Stock Score of Bausch + Lomb Corp

Currency: USD Updated: 2026-06-29

Key Insights

Bausch + Lomb Corp's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 74 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 18.09.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Bausch + Lomb Corp's Score

Industry at a Glance

Industry Ranking
74 / 204
Overall Ranking
179 / 4570
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Bausch + Lomb Corp Highlights

StrengthsRisks
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 23.03% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 5.10B.
Undervalued
The company’s latest PE is -26.97, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 40.30M shares, decreasing 38.29% quarter-over-quarter.
Held by Larry Robbins
Star Investor Larry Robbins holds 1.93M shares of this stock.

Analyst Rating

Based on 12 analysts
Hold
Current Rating
18.091
Target Price
+8.78%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

FAQs

How does TradingKey generate the Stock Score of Bausch + Lomb Corp?

The TradingKey Stock Score provides a comprehensive assessment of Bausch + Lomb Corp based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Bausch + Lomb Corp’s performance and outlook.

How do we generate the financial health score of Bausch + Lomb Corp?

To generate the financial health score of Bausch + Lomb Corp, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Bausch + Lomb Corp's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Bausch + Lomb Corp.

How do we generate the company valuation score of Bausch + Lomb Corp?

To generate the company valuation score of Bausch + Lomb Corp, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Bausch + Lomb Corp’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Bausch + Lomb Corp’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Bausch + Lomb Corp.

How do we generate the earnings forecast score of Bausch + Lomb Corp?

To calculate the earnings forecast score of Bausch + Lomb Corp, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Bausch + Lomb Corp’s future.

How do we generate the price momentum score of Bausch + Lomb Corp?

When generating the price momentum score for Bausch + Lomb Corp, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Bausch + Lomb Corp’s prices. A higher score indicates a more stable short-term price trend for Bausch + Lomb Corp.

How do we generate the institutional confidence score of Bausch + Lomb Corp?

To generate the institutional confidence score of Bausch + Lomb Corp, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Bausch + Lomb Corp’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Bausch + Lomb Corp.

How do we generate the risk management score of Bausch + Lomb Corp?

To assess the risk management score of Bausch + Lomb Corp, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Bausch + Lomb Corp’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Bausch + Lomb Corp.
KeyAI